4Capuano B, Crosby IT, Lloyd EJ. Schizophrenia: genesis, receptorology and current herapeutics[ J ]. Curr Med Chem, 2002,9(5) : 521 - 548.
5Schmidt AW, Lebel LA, Howard HR Jr, et al. Ziprasidone: a novel antipsychotic agent with aunique human receptor binding profile[ J ]. Eur J Pharmacol, 2001,425 (3) : 197 - 201.
6Miceli JJ, Wilner KD, Hansen RA, et al. Single- and multipledose pharrnacokinetics of 2iprasidone under non-fasting conditions in healthy male volunteers [ J ]. Br J Clin Pharmacol, 2000,49(Suppl 1) :S5 - S13.
7Miceli JJ,Hunt T,Cole MJ, et al. The pharmacokinetics of CP-88,059 in healthy male volunteers following oral and intravenous administration(abstract) [ J ]. Clin Pharmacol Ther, 1994,62 :142.
8Prakash C,Kamel A,Gummerus J, et al. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans[J].Drug Metab Dispos, 1997,25(7) :863 - 872.
9Wilner KD, Tensfeldt TG, Baris B, et al. Single- and multipledose pharmacokinetics of ziprasidone in healthy young and elderly volunteers[J]. Br J Clin Pharmacol,2000,49(Suppl 1 ) : S15 -S20.
10Aweeka F, Jayesekara D, Horton M, et al. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function[J]. Br J Clin Pharmacol,2000,49(Suppl 1) :S27 - S33.
